Persistence of peripheral blood Vγ9Vδ2-T cells appeared to be further reduced in mice treated with the CD1d-Vδ2 bsTCE, possibly as a result of redistribution to (tumor) tissue, TCR downregulation, or activation-induced cell death. Here, CD1D is linked to neoplasm.